The second quarter revenues also indicate a 32 percent increase over the first quarter of 2012. Bill Taylor, president and COO of MiMedx, attributed this growth to increasing demand and sales of the company’s AmnioFix and EpiFix allografts.
More Articles on Orthopedic Devices:
Cleveland Clinic Receives $2.8M for Orthopedic Initiatives
Study: Regulations, Taxes Pose New Challenges for US Medical Device Industry
Moving Forward With Cartilage Regeneration: Q&A With Regentis CEO Dr. Alastair Clemow
